Glucocorticoid-related AEs and costs increase with dose
- PDF / 170,157 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 28 Downloads / 198 Views
1
Glucocorticoid-related AEs and costs increase with dose Oral glucocorticoid (OGC)-related adverse events (AEs) and associated healthcare costs in patients with giant cell arteritis (GCA) increase with the cumulative dose, according to findings of a Genentech-funded study published in ClinicoEconomics and Outcomes Research. Data from US MarketScan Commercial and Medicare Supplemental claims databases were used to identify 1602 patients with newly diagnosed GCA who filled at least one prescription for OGC between 2009 and 2014. The incidence of AEs (aseptic osteonecrosis; fracture [vertebral or nonvertebral]; gastrointestinal haemorrhage, perforation or ulcer; hospitalisation due to myocardial infarction or stroke; hospitalisation for pneumonia or serious infection; osteoporosis; or type 2 diabetes mellitus) and direct healthcare costs due to AEs were investigated over a one-year follow-up period in patients who received cumulative OCG doses of 7200mg. The mean cumulative dose was 5806mg. Overall, 36.5% of patients developed potential OGC-related AEs, and the incidence of AEs increased from 30.7% to 45.3% across cumulative dose groups. Unadjusted one-year healthcare costs in patients with AEs totalled $12 818* per patient. Multivariate analysis found that AE-related healthcare costs increased significantly as the cumulative dose increased (p
Data Loading...
